DE60042026D1 - Virale replikons und von induzierenden wirkstoffen abhängige viren - Google Patents

Virale replikons und von induzierenden wirkstoffen abhängige viren

Info

Publication number
DE60042026D1
DE60042026D1 DE60042026T DE60042026T DE60042026D1 DE 60042026 D1 DE60042026 D1 DE 60042026D1 DE 60042026 T DE60042026 T DE 60042026T DE 60042026 T DE60042026 T DE 60042026T DE 60042026 D1 DE60042026 D1 DE 60042026D1
Authority
DE
Germany
Prior art keywords
replicon
gene
hiv1
rtta
ltrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60042026T
Other languages
English (en)
Inventor
Benjamin Berkhout
Koenraad Dirk Verhoef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academisch Medisch Centrum Bij de Universiteit van Amsterdam
Academisch Medisch Centrum
Original Assignee
Academisch Medisch Centrum Bij de Universiteit van Amsterdam
Academisch Medisch Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Medisch Centrum Bij de Universiteit van Amsterdam, Academisch Medisch Centrum filed Critical Academisch Medisch Centrum Bij de Universiteit van Amsterdam
Application granted granted Critical
Publication of DE60042026D1 publication Critical patent/DE60042026D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60042026T 1999-09-10 2000-09-08 Virale replikons und von induzierenden wirkstoffen abhängige viren Expired - Fee Related DE60042026D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202971A EP1083230A1 (de) 1999-09-10 1999-09-10 Virale Replikons und von induzierenden Wirkstoffen abhängige Viren
PCT/NL2000/000637 WO2001020013A2 (en) 1999-09-10 2000-09-08 Viral replicons and viruses dependent on inducing agents

Publications (1)

Publication Number Publication Date
DE60042026D1 true DE60042026D1 (de) 2009-05-28

Family

ID=8240635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042026T Expired - Fee Related DE60042026D1 (de) 1999-09-10 2000-09-08 Virale replikons und von induzierenden wirkstoffen abhängige viren

Country Status (9)

Country Link
US (1) US20030099613A1 (de)
EP (2) EP1083230A1 (de)
JP (1) JP2003509059A (de)
AT (1) ATE428792T1 (de)
AU (1) AU780984B2 (de)
CA (1) CA2386530A1 (de)
DE (1) DE60042026D1 (de)
WO (1) WO2001020013A2 (de)
ZA (1) ZA200201923B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1479774A1 (de) * 2003-05-20 2004-11-24 Academisch Medisch Centrum Viren die induzierende Wirkstoffe für den Zelleintritt benötigen
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
CA2630348C (en) * 2005-11-17 2016-01-12 Stichting Voor De Technische Wetenschappen Inducible expression systems
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
PT2540820T (pt) 2005-12-09 2018-03-02 Academisch Medisch Centrum Bij De Univ Van Amsterdam Meios e métodos para influenciar a establidade de células produtoras de anticorpos
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
WO2011008093A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
EP2319918B1 (de) * 2009-11-10 2013-01-16 Centre National De La Recherche Scientifique Vektor auf Lentivirus beruhend und dessen Verwendung bei der zielgerichteten Evolution von genomischen Regionen, Genen und Polynukleotiden
HUE033141T2 (en) 2010-12-02 2017-11-28 Aimm Therapeutics Bv Instruments and methods for producing high affinity antibodies
JP6747975B2 (ja) 2014-01-31 2020-08-26 アイム・セラピューティクス・べー・フェー 安定な抗体を産生するための手段及び方法
CN111521359A (zh) * 2020-04-29 2020-08-11 河南工程学院 面向结构振动主动控制优化配置方法及振动控制实验平台

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4100594A1 (de) * 1991-01-08 1992-07-09 Inst Genbiologische Forschung Neue plasmide zur zeitlichen und oertlichen kontrollierten expression eines heterologen produktes in pflanzen
PT584348E (pt) * 1992-03-11 2005-10-31 Powderject Vaccines Inc Vacina genetica para virus da imunodeficiencia
US5723765A (en) * 1994-08-01 1998-03-03 Delta And Pine Land Co. Control of plant gene expression
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US5965440A (en) * 1995-12-07 1999-10-12 The General Hospital Corporation Controlled gene product delivery from a regulatable retroviral vector
WO1997048277A1 (en) * 1996-06-20 1997-12-24 The Salk Institute For Biological Studies Modular assembly retroviral vectors and uses thereof
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
CA2354195C (en) * 1998-12-22 2012-07-17 Dow Agrosciences Llc Methods and genetic compositions to limit outcrossing and undesired gene flow in crop plants
EP1203088B1 (de) * 1999-07-28 2005-03-30 Stephen Smith Konditionell kontrollierter, attenuierter hiv-1 impfstoff

Also Published As

Publication number Publication date
AU7459500A (en) 2001-04-17
US20030099613A1 (en) 2003-05-29
WO2001020013A3 (en) 2001-09-27
JP2003509059A (ja) 2003-03-11
ZA200201923B (en) 2003-09-23
CA2386530A1 (en) 2001-03-22
ATE428792T1 (de) 2009-05-15
EP1212446B1 (de) 2009-04-15
AU780984B2 (en) 2005-04-28
WO2001020013A2 (en) 2001-03-22
EP1083230A1 (de) 2001-03-14
EP1212446A2 (de) 2002-06-12

Similar Documents

Publication Publication Date Title
DE60042026D1 (de) Virale replikons und von induzierenden wirkstoffen abhängige viren
ES2706899T3 (es) Vectores de terapia génica y citosina desaminasas
Das et al. The HIV-1 Tat protein has a versatile role in activating viral transcription
Hoffmann et al. Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells
DE69230882D1 (de) Cytosindeaminase negatives selektionssystem zur genübertragung und therapien
DE69128077D1 (de) Nuklein-säure amplifikation mit dns abhängigen rns polymerasen aktivität von rns-replikasen
ZA200007403B (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals.
Bartholomeeusen et al. A chikungunya virus trans-replicase system reveals the importance of delayed nonstructural polyprotein processing for efficient replication complex formation in mosquito cells
DK0935660T3 (da) Infektiöse kloner af RNA-virusser og vacciner og deraf afledte diagnostiske assays
DK0544894T3 (da) Anvendelse af exo-prøve-nukleotider i genkloning
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
ES2094744T3 (es) Manipulaciones geneticas con el adn recombinante que contiene secuencias derivadas de los virus arn.
Marzio et al. Efficient human immunodeficiency virus replication requires a fine-tuned level of transcription
ATE292186T1 (de) Konditionell kontrollierter, attenuierter hiv-1 impfstoff
Lund et al. The kissing-loop motif is a preferred site of 5′ leader recombination during replication of SL3-3 murine leukemia viruses in mice
Das et al. Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication
van der Velden et al. Tat has a dual role in simian immunodeficiency virus transcription
DE69434830D1 (de) Zur verleihung viraler resistenz an pflanzen geeignetes polyribozym und dieses polyribozym produzierende resistente pflanzen
Stephens et al. Simian-human immunodeficiency virus (SHIV) containing the nef/long terminal repeat region of the highly virulent SIVsmmPBj14 causes PBj-like activation of cultured resting peripheral blood mononuclear cells, but the chimera showed No increase in virulence
Ebina et al. Perspectives of genome-editing technologies for HIV therapy
Dufresne et al. Genetically stable picornavirus expression vectors with recombinant internal ribosomal entry sites
Wang et al. G3BP/Rin-binding motifs inserted into flexible regions of nsP2 support RNA replication of Chikungunya virus
Yoshida et al. HIV-1 RNAs whose transcription initiates from the third deoxyguanosine of GGG tract in the 5′ long terminal repeat serve as a dominant genome for efficient provirus DNA formation
Orlinger et al. Selection and analysis of mutations in an encephalomyocarditis virus internal ribosome entry site that improve the efficiency of a bicistronic flavivirus construct
Bialek et al. CRISPR-Cas9-based genome engineering to generate Jurkat reporter models for HIV-1 infection with selected proviral integration sites

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee